Detailed Information
Cited 7 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.
- Authors
- Lee, KW[Lee, Keun Wook]; Bai, LY[Bai, Li-Yuan]; Jung, M[Jung, Minkyu]; Ying, J[Ying, Jieer]; Im, YH[Im, Young Hyuck]; Oh, DY[Oh, Do-Youn]; Cho, JY[Cho, Jae Yong]; Oh, SC[Oh, Sang Cheul]; Chao, Y[Chao, Yee]; Li, H[Li, Huiyan]; Zhou, P[Zhou, Ping]; Bao, Y[Bao, Yuanyuan]; Kang, YK[Kang, Yoon-Koo]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.